Jupiter Neurosciences, INC. 8-K/A Filing
Ticker: JUNS · Form: 8-K/A · Filed: Nov 20, 2025 · CIK: 1679628
Sentiment: neutral
Filing Stats: 4,713 words · 19 min read · ~16 pages · Grade level 17.9 · Accepted 2025-11-20 16:05:28
Key Financial Figures
- $0.0001 — and outstanding shares of common stock, $0.0001 par value (the "Common Stock") of the C
- $20.0 million — as the right to sell to Yorkville up to $20.0 million of its common stock, par value $0.0001
- $6.0 m — agreed to advance to the Company up to $6.0 million, less certain amounts as describe
- $3,720,000 — first Pre-Paid Advance in the amount of $3,720,000 was disbursed to the Company on October
- $4.0 m — ertible Note in the principal amount of $4.0 million, which was issued with an "origin
- $280,000 — nal issue discount" ("OID") of 7.0% (or $280,000) and is initially convertible into Comm
- $1.50 — on Stock at a fixed conversion price of $1.50 per share (subject to adjustment as pro
- $1,860,000 — f the Pre-Paid Advance in the amount of $1,860,000 will be disbursed to the Company on the
- $2.0 m — ertible Note in the principal amount of $2.0 million, which will likewise be issued wi
- $140,000 — n "original issue discount" of 7.0% (or $140,000) and will also be initially convertible
- $25,000 — cash "structuring fee" in the amount of $25,000 and (ii) upon execution of the SEPA, is
- $200,000 — a total aggregate dollar value equal to $200,000, or 1.0% of Yorkville's $20.0 million a
- $1.5162 — ommitment Share valued at approximately $1.5162 per share, representing the VWAP on Oct
- $18,000 — ny through any Pre-Paid Advance and (b) $18,000 per month, on an accrual basis, for a p
- $5.0 million — able at such time as the Company raises $5.0 million or more in additional financing. This
Filing Documents
- form8-ka.htm (8-K/A) — 79KB
- ex4-1.htm (EX-4.1) — 133KB
- ex10-3.htm (EX-10.3) — 22KB
- 0001493152-25-024454.txt ( ) — 447KB
- juns-20251024.xsd (EX-101.SCH) — 3KB
- juns-20251024_lab.xml (EX-101.LAB) — 33KB
- juns-20251024_pre.xml (EX-101.PRE) — 22KB
- form8-ka_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 19, 2025 Jupiter Neurosciences, Inc. By: /s/ Christer Rosn Name: Christer Rosn Title: Chairman and Chief Executive Officer